Ana-Maria Vladareanu

Ana-Maria Vladareanu

Auto-generated profile, based on publicly available information

Ana-Maria Vladareanu

Hematology, Emergency University Hospital of Bucharest , “Carol Davila” University of Medicine and Pharmacy , Bucharest , Romania

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2017 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
ATAdrian Trifa
Adrian Trifa
CBClaudia Bănescu
Claudia Bănescu
ABAnca Bojan
Anca Bojan
CVCristian M. Voina
Cristian M. Voina
ȘPȘtefana Popa
Ștefana Popa
RPRadu Anghel Popp
Radu Anghel Popp
Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are classical myeloproliferative neoplasms (MPN), characterized by specific somatic mutations in JAK2, CALR or MPL genes. JAK2 46/1 and TERT rs2736100 polymorphisms are known to significantly predispose to MPN. This study aimed to establish the additional contribution of the recently described MECOM rs2201862, HBS1L‐MYB rs9376092 and THRB‐RARB rs4858647 polymorphisms to the occurrence of MPN. These three polymorphisms, along with JAK2 46/1 and TERT rs2736100 were genotyped in 939 MPN patients (454 with ET, 337 with PV and 148 with PMF) and 483 controls. MECOM rs2201862 associated significantly with each MPN entity, except for ET, and with all major molecular sub‐types, especially those CALR‐mutated (OR = 1.4; 95% CI = 1.1‐1.8; P‐value = .005). HBS1L‐MYB rs9376092 associated only with JAK2 V617F‐mutated ET (OR = 1.4; 95% CI = 1.1‐1.7; P‐value = .003). THRB‐RARB rs4858647 had a weak association with PMF only (OR = 1.5; 95% CI = 1‐2.1; P‐value = .04). Surprisingly, JAK2 46/1 haplotype was associated significantly not only with JAK2 V617F‐mutated MPN, but also with CALR‐mutated MPN (OR = 1.4; 95% CI = 1.1‐1.8; P‐value = .01). TERT rs2736100 was associated equally strong with all MPN, regardless of phenotype or molecular sub‐type. In conclusion, JAK2 46/1, TERT rs2736100 and MECOM rs2201862 are the chief predisposing polymorphisms to MPN.

20 October 2023 in Turkish Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
AVAna-Maria Vlădăreanu
Ana-Maria Vlădăreanu
MOMinodora Onisai
Minodora Onisai
IIIuliana Iordan
Iuliana Iordan
EREugen Radu
Eugen Radu
ARAdrian Eugen Rosca
Adrian Eugen Rosca
MCMonica Mihaela Cirstoiu
Monica Mihaela Cirstoiu
Objectives: To assess the frequency of multiple thrombophilia-associated mutations and polymorphisms in a selected population of high-risk pregnancies. Methods: Thrombophilia screening was performed for 1,500 pregnant women with prior pregnancy complications or thrombotic events. Nine thrombophilia-associated mutations or polymorphisms were screened: factor V Leiden, factor V H1299R, prothrombin G20210A, MTHFR C677T, MTHFR A1298C, factor XIII V34L, PAI-1 4G/5G polymorphisms, EPCR G4600A, EPCR C4678G. Results: Out of the 1,500 patients, 1,291 fulfilled the criteria for data interpretation. All patients had low-risk thrombophilia-associated genetic variants. Only 1.24 % of cases presented high-risk abnormalities (homozygous factor V Leiden/prothrombin G20210A, or both mutations in heterozygous form). Heterozygous factor V Leiden occurred in 10.38 % of cases, while only 5.81 % carried heterozygous prothrombin G20210A mutation. The frequency of prothrombin G20210A mutation was higher (10.37 %) in the subgroup associating factor V Leiden, than in the subgroup lacking it (5.36 %). Low-risk genetic variants occurred with a higher frequency: 23.78 % factor V H1299R, 57.32 % MTHFR C677T, 55.54 % MTHFR A1298C, 44.07 % factor XIII V34L, 73.20 % PAI-1 4G/5G polymorphisms, 69.64 % EPCR G4600A, and 69.63 % EPCR C4678G. Conclusions: All patients had at least one prothrombotic genetic mutation or variant. Our data highlight the need for thrombophilia screening, including low-risk genetic variants, in a high-risk population of pregnant women with a history of pregnancy complications or thrombotic events.

1 October 2009 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
PDF file
MOMinodora Onisai
Minodora Onisai
RVR. Vladareanu
R. Vladareanu
AVA. Vladareanu
A. Vladareanu
HBHoria Bumbea
Horia Bumbea
MNMarta Aldea Novo
Marta Aldea Novo
MCM. Ciorascu
M. Ciorascu

30 July 2024 in Documenta Haematologica - Revista Romana de Hematologie
Verified
Journal Article
Closed access
AIAna-Maria Ilinescu
Ana-Maria Ilinescu
AVAna-Maria Vladareanu
Ana-Maria Vladareanu
EEElena Georgiana Ene
Elena Georgiana Ene
IIIuliana Iordan
Iuliana Iordan
HBHoria Bumbea
Horia Bumbea
Autologous stem cell transplantation (ASCT) has become more prevalent for high-grade non-Hodgkin's lymphoma (NHL) over the past decade. ASCT serves as a salvage treatment for high-risk or relapsed patients, offering potential long-term remission. Cutaneous modifications post-ASCT can be classified as early (within 100 days) and late (after 100 days). Understanding these changes is crucial for timely diagnosis and management. Early modifications typically include transient erythema, hyperpigmentation, and acute dermatitis, often linked to the conditioning regimen. Late modifications, occurring months to years posttransplantation, can encompass chronic skin changes such as scleroderma-like features and persistent pigmentary alterations. Emerging evidence challenges the notion that ASCT is free of graft-versus-host disease (GVHD), with incidences of auto-GVHD reported. However, cutaneous GVHD post-ASCT, though uncommon, poses significant diagnostic challenges. Cutaneous GVHD manifestations range from mild eruptions to severe, systemic involvement. The role of skin biopsy in these cases is invaluable, providing histopathological confirmation and distinguishing GVHD from other dermatoses. Recognizing the early and late cutaneous modifications following ASCT is essential for clinicians. Despite the rarity of skin GVHD in ASCT, awareness and prompt biopsy can facilitate accurate diagnosis and appropriate management, improving patient outcomes.